Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).
David Ferry(Eli Lilly (United States)), Gérard Lledo(American Society of Clinical Oncology), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Salvatore Siena(University of Milan), Sandrine Brette, Pascale Garreau-Laporte(Sanofi (France)), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto F. Sobrero(Ospedale Policlinico San Martino), Emmanuelle Dochy(Sanofi (Belgium)), Roberto Bordonaro(Ospedale Garibaldi)
Cited by 3
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914